PharmaCliff
Tuesday 06:00 UTC · Weekly digest

The patent-cliff workspace for mid-tier generics teams.

Search 30,000+ expiring pharma patents, watch the ones that move, and get a verdict-led digest every Tuesday. FDA Orange Book + USPTO + EPO INPADOC. From €39/mo, no demo call.

See the sample digestPricing — from €39/mo →

Five public registries — FDA · USPTO · EPO · WIPO · Google Patents·Beta AI · founding tier capped at 50 seats·No demo calls — try the product

Digest · this week · row 1 of 24HIGH ×4MED ×9LOW ×11
High
Sacubitril / valsartan — combination of use & salt form
holder Novartis Pharma AGexpiry 2026-06-15family US, EP, JP, KR (12 members)USPTO US 8,101,659 B2
orange-book ANDA route openfamily-size 12claims narrow, salt-form bypass plausibleCPC A61K 31/4178

Why HIGH: Orange Book lists an ANDA-receptive route via the dihydrate salt; the active-ingredient claim narrows around the co-crystal, leaving a viable formulation play for any team already running an ARNI program. Family expires within 7 months across all five PharmaCliff jurisdictions — synchronized cliff, low IP-divergence risk.

87
Relevance
Index · Q3–Q4 2026 cliff window

Five molecules from this week's index.

All five are drawn from PharmaCliff's current 30,000-patent index. The full digest ranks 24 patents each Tuesday with verdict, signals, and a 100-word analysis.

Drug / moleculeExpiryHolderJurisdictionsStatus
Sacubitril / valsartan A61K 31/4178 · ARNI2026-06NovartisUS · EPHigh
Trastuzumab-emtansine C07K 16/32 · HER2 ADC2026-08Genentech / RocheUS · EP · JP · KRHigh
Semaglutide (CV-use indication) A61K 38/26 · GLP-12026-10Novo NordiskUSMedium
Tiotropium (inhaled formulation) A61K 9/00 · LAMA2026-03Boehringer IngelheimUS · EPUpcoming
Bictegravir / TAF / FTC A61K 31/505 · ARV combo2026-04Gilead SciencesUS · EPUpcoming
All five drawn from PharmaCliff's current index. The full digest opens the rest.
Methodology · public

Every source named. Every cron disclosed.

The competitor set treats data provenance like a moat. PharmaCliff treats it like a checklist. If a verdict goes in front of a Director of IP, the ingest path is owed to them.

Patents indexed
30,142

Pharma + biotech, CPC-pre-filtered against 14 therapeutic-area anchors.

Orange Book matched
329

Linked to live ANDA opportunities — real generic-launch candidates, not theoretical filings.

Jurisdictions
US · EP · JP · KR · WO

INPADOC family linkage adds IN, CN, BR reach when a family member is present.

Send window
Tue 06:00 UTC

Indexes refresh daily. Digest assembled Monday, AI-scored, subscriber feedback tunes the rubric.

FDA Orange Bookfda.gov/cder/obPatent + exclusivity listings tied to approved NDAs and ANDA opportunity routes.refresh · daily
USPTO PAIRpatentcenter.uspto.govApplication file wrappers, term adjustments, maintenance status. Bulk weekly + on-demand re-pull.weekly + on-demand
EPO INPADOCepo.org/inpadocCross-jurisdiction patent families. The piece that makes US/EP/JP/KR alignment honest.weekly
Google Patents BigQuerypatents-public-dataHistorical backfill and CPC normalization. Used to seed the index, not to score.monthly · historical
Read the full methodology — sources, scoring rubric, curation rules
Who reads it

Three jobs. One Tuesday email.

PharmaCliff isn't a platform — it's a curated read. Each persona below has one specific reason to keep the subscription past month two.

Generics R&D Lead

Decide which 2026–2028 expiries to invest formulation work in this quarter.

HIGH-verdict rows surface molecules where the active-ingredient cliff and the regulatory route line up — the only intersection worth a formulation team's time.

e.g. ARNI co-crystal bypass, ADC linker class
IP Portfolio Manager

Spot competitor cliffs in your therapeutic areas before they hit FDA submission queues.

Filter the digest to your TA anchors. Family-level expiry maps tell you when a competitor's defensive wall actually breaks — not just when one US claim ages out.

e.g. oncology, cardiometabolic, CNS
BD / Licensing Scout

Surface multi-jurisdiction family convergence for partnership conversations.

INPADOC convergence — five-jurisdiction synchronized cliffs — is the signal you bring to a licensing call. The digest highlights them, you bring the deal.

e.g. in-licensing scouts, regional manufacturer partnerships
Pricing · all tiers visible

Three tiers. No demo wall.

Every competitor in this list — DrugPatentWatch, PatSnap, IPlytics, GreyB — hides their price. PharmaCliff doesn't. If you can't see what it costs before you click, that's the product telling you it's not for you.

Founding · lifetime

For the first fifty subscribers.

€39/ month · billed yearly · price locked for life
  • Weekly digest, every Tuesday, full archive
  • All five jurisdictions, all therapeutic areas
  • Subscriber feedback shapes the scoring rubric
  • Price never increases for founding members
  • Cap: 50 seats, then closed forever
Reserve a founding seat

No card required to read the sample digest first.

Beta

For teams who want in before standard pricing lands.

€69/ month · billed yearly
  • Weekly digest + full archive
  • All jurisdictions, choose up to 4 TA anchors
  • Beta-priced through the AI-scoring v2 release
  • Roll to standard pricing at GA, not retroactively
Try the sample first

Cancel anytime, refund within 30 days.

Standard

The price after general availability.

€129/ month · billed yearly
  • Weekly digest + full archive + API export
  • All jurisdictions, all TA anchors
  • Quarterly methodology update calls
  • Available from GA — not yet open
Read sample · join waitlist

GA target: when AI scoring exits beta.

0 of 50FOUNDING SEATS RESERVEDPre-launch · transparent counter — not embarrassing, just honest.